Liver function and energy metabolism in hepatocellular carcinoma developed in patients with hepatitis B-related cirrhosis

Meixin Ren, MS∗, Juan Li, MS∗, Ran Xue, MS‖, Zhongying Wang, BS∗, Shengli Li Coll, BS∗, Qinghua Meng, MD‡,§

Abstract

Energy metabolism in patients with Hepatocellular carcinoma (HCC) accompanying by hepatitis B cirrhosis is unknown. To compare the differences in liver functions and energy metabolism between patients with hepatitis B-related cirrhosis and patients with HCC.

This was a retrospective study of patients with hepatitis B-related cirrhosis (LC group, n = 75) and patients with HCC accompanying by hepatitis B cirrhosis (HCC group, n = 80) treated in Beijing You’an Hospital between January 2013 and June 2017. The resting energy expenditure (REE), respiratory quotient (RQ), carbohydrate oxidation rate (CHO%), fat oxidation rate (FAT%), and protein oxidation rate (PRO%) were measured using a metabolic cart. Liver function, renal function, blood coagulation, etc. were collected.

Compared to the LC group, patients with HCC had normal metabolism, but RQ (0.83 ± 0.07 vs 0.85 ± 0.08, P = .073) and CHO% (35.5% vs 49%, P = .013) were lower and FAT% was higher (41% vs 33%, P = .030). Compared with patients with LC group, albumin (ALB), γ-glutamyltranspeptidase (GGT), alkaline phosphatase (AKP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and prothrombin time activity (PTA) were elevated in the HCC group, while total bilirubin (TB), total bile acid (TBA), and international normalized ratio (INR) were reduced (P < .05). Cholinesterase (CHE) was positively correlated with RQ, CHO, and CHO% (P < .05), while negatively correlated with FAT and FAT% (P < .05). AKP was negatively correlated with RQ, CHO, and CHO% (P < .05), while positively correlated with FAT and FAT% (P < .05). TBA was negatively correlated with RQ and CHO (P < .05), while positively correlated with FAT (P < .05).

HCC leads to increased liver synthetic function and improve the liver functions of patients with LC, at least to some extent, but the nutritional metabolism was poor.

Abbreviations: AFP = alpha-fetoprotein, AKP = alkaline phosphatase, ALB = albumin, ALT = alanine aminotransferase, APASL = Asian Pacific Association for the Study of the Liver, Apo A1 = Apolipoprotein A-1, Apo B = Apolipoprotein B, AST = aspartate aminotransferase, BCLC = Barcelona Clinic Liver Cancer, BMI = body mass index, CHE = cholinesterase, CHO = carbohydrate oxidation, CHO% = carbohydrate oxidation rate, CREA = creatinine, DB = direct bilirubin, FAT = fat oxidation, FAT% = fat oxidation rate, GGT = γ-glutamyltranspeptidase, GLOB = globulin, HCC = Hepatocellular carcinoma, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density lipoprotein cholesterol, MREE = measured rest energy expenditure, REE = resting energy expenditure, RQ = respiratory quotient, TB = total bilirubin, TBA = total bile acid, TC = total cholesterol, TG = triglyceride.

Keywords: carbohydrate oxidation, cirrhosis, energy metabolism, fatty acid oxidation, hepatitis B, hepatocellular carcinoma, protein oxidation

Editor: Simona Gurzu.

Meixin Ren and Juan Li contributed equally to this work.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This study was supported by the National Natural Science Foundation of China (No. 81470877).

The authors declare that they have no conflicts of interest.

∗Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, ‡Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Correspondence: Qinghua Meng, Department of Critical Care Medicine of Liver Disease, Beijing You-An Hospital, Capital Medical University, Beijing, China (e-mail: wj5773@163.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2019) 98(19):e15528

Received: 7 September 2018 / Received in final form: 1 April 2019 / Accepted: 8 April 2019

http://dx.doi.org/10.1097/MD.0000000000015528
1. Introduction

The liver is the central metabolic organ in the human body. Patients with liver cirrhosis have liver damage and varying degrees of abnormalities in energy metabolism.\[^{[1]}\] Previous studies have shown that patients with cirrhosis are in a low metabolic state characterized by low glucose oxidation rate (CHO\%) and with the main energy supply being proteins.\[^{[1–5]}\]

With the aggravation of cirrhosis, CHO\% decreases significantly, resting energy expenditure (REE) and respiratory quotient (RQ) tend to decrease, while protein oxidation rate (RPO\%) increases.\[^{[1–4]}\] The Child-Pugh classification is negatively correlated with REE, RQ, and CHO\%.\[^{[4]}\]

Hepatocellular carcinoma (HCC) occurs all over the world, mainly in the Asia-Pacific coast and southeastern Africa, while Australia, Europe, North America and other regions are low incidence areas.\[^{[5]}\] Hepatocellular carcinoma (HCC) accounts for more than 90\% of malignant liver tumors, it is the fifth cancer in term of incidence rate worldwide, and the third leading cause of mortality. In China, HCC ranks fourth among the malignant tumors and is the third cause of cancer-related death, representing a serious public health issue.\[^{[6,7]}\] HCC is closely associated with cirrhosis. The prevalence of cirrhosis in patients with HCC is 84.6\% and the incidence of HCC after liver cirrhosis is 49.9\%.\[^{[8]}\]

Although the pathogenesis of malignant tumors has not yet been elucidated, there is increasing evidence that malignant tumors are a metabolic-related disease.\[^{[9]}\] Patients with malignant tumors are generally in a state of high metabolism, with increased mobilization of endogenous fat, decreased glucose utilization, consumption of fat and fat-free masses, and loss of somatic cell population. An early study by Dagnelie et al.\[^{[10]}\] showed that gluconeogenesis in the liver increases in tumor patients with distant metastasis. Leifers et al.\[^{[11]}\] showed that patients with colorectal cancer have high liver and tumor metabolism, causing cachexia in the last few months of their lives. Guglielmi et al.\[^{[12]}\] showed that well-nourished cirrhosis and HCC display normal oxidative patterns. Recent metabolomics studies have identified some abnormal metabolites and pathways in patients with cirrhosis and HCC.\[^{[13–25]}\] Nevertheless, there are few studies on the comparison of poor metabolic indicators between patients with HCC and patients with liver cirrhosis.

It is well known that end-stage liver diseases are accompanied by severe loss of liver functions. With advancing degree of cirrhosis, the treatment opportunities of HCC are gradually lost and prognosis worsens. Liver tissue would be more damaged if HCC occurs on the basis of liver cirrhosis, which is undoubtedly a “disaster” for the patients. On the other hand, it can be observed that liver functions are still good for some patients with large HCC, while liver functions worsens for some patients with HCC of Child-Pugh grade A after HCC resection, with a high risk of liver failure. Improvement of liver functions in patients with liver cirrhosis and HCC could lead to the hypothesis of “compensation for liver functions” for HCC and cirrhosis. Whether palliative therapy should be considered for these patients to avoid decompensation of liver functions and even liver failure after surgical resection of large HCC could be explored.

Therefore, this study aimed to examine the differences of liver functions and energy metabolism between patients with hepatitis B-related cirrhosis and patients with HCC, as well as to investigate the relationship between liver functions and energy metabolism. The results could provide a basis for better nutritional support of HCC patients and for the selection of clinical treatment regimens for these patients.

2. Methods

2.1. Study design and patients

This was a retrospective study. The subjects were patients with hepatitis B virus-associated cirrhosis (LC group) and patients with HCC (HCC group) treated at the Beijing You’an Hospital from January 2013 to June 2017. This study was approved by the Ethics Committee of Beijing You’an Hospital. This study was reviewed and approved by the medical research ethics committee of Beijing You’an Hospital, Capital Medical University.

**Inclusion criteria**: Patients with hepatitis-B cirrhosis and hepatitis B-related HCC of 18 to 65 years of age. The diagnostic criteria of hepatitis-B cirrhosis referred to the guideline of the Asian Pacific Association for the Study of the Liver (APASL) in 2012.\[^{[16]}\] The diagnostic criteria for HCC referred to the clinical practice guide of the Asia Pacific Hepatocellular Carcinoma Association (2017 edition).\[^{[17]}\]

**Exclusion criteria**: 1. Patients combined with or overlapped with other viral infections: positive result for any one of anti-HAV-IgM, anti-HCV, anti-HDV, anti-HIV, CMV, EBV, or anti-HIV.
2. Patients combined with diseases such as thyroid disease, kidney disease, active tuberculosis, mental illness, and other malignant tumors.
3. Patients who used adrenal cortex hormones or bronchodilators such as β-agonists and theophylline within 12 hours, as well as patients who drank caffeinated drinks such as tea and coffee.
4. Patients combined with other liver diseases such as alcoholic liver disease, fatty liver disease, drug liver disease, and autoimmune hepatitis.
5. Patients combined with severe hydrothorax and ascites, as well as severe infections, etc.

2.2. Grouping

1. According to the Child-Pugh classification,\[^{[18]}\] grade A was 5–6 points, grade B was 7–9 points and grade C was ≥10 points. The LC and HCC groups were divided into 3 subgroups, respectively: the LC-A, HCC-A, LC-B, HCC-B, LC-C, and HCC-C groups.

2. Tumor staging: Based on Barcelona Clinic Liver Cancer Staging System (BCLC),\[^{[19]}\] the patients in the HCC group were divided into the 4 groups (HCC-1, HCC-2, HCC-3, and HCC-4) groups according to the A, B, C, and D stages.

2.3. Data collection

All data were obtained from the HSP 2008 system of the Beijing You’an Hospital. Liver functions were tested using an AU5400 automatic biochemical analyzer (Olympus, Tokyo, Japan). Results of routine liver functions were obtained from biochemical examination, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), alkaline phosphatase (AKP), γ-glutamyltranspeptidase (GGT), albumin (ALB), cholinesterase (CHE), and total bile acid (TBA). Blood coagulation was tested using a CA-7000 automatic blood coagulation instrument (Sysmex, Kobe, Japan). All clinical
biochemical measurements were performed using an AU5400 automatic biochemical analyzer (Olympus, Tokyo, Japan), including prothrombin time activity (PTA). All instruments were operated using the manufacturers’ reagents and instructions.

2.4. Metabolic measurements

Indirect measurement of energy metabolism was determined using a CCM/D nutritional metabolism test system (referred to as metabolic cart) (MGC Diagnostics Corp., Saint Paul, MN). The patients were required to be fasting for 8 to 10 hours. The patients were in the supine position. The test was performed 30 minutes after avoiding muscle activity with an ambient temperature of 24 to 26°C, humidity of 45% to 60% and atmospheric pressure of 101 to 102.4 kPa. The exhaled gas was collected using hood ventilation, which was recorded once every 2 to 5 seconds. The average O2 consumption and CO2 production per minute were calculated automatically. Each test was performed for 15 to 20 minutes. The subjects were required to remain awake during the entire test and be as quiet as possible.

The actual measurement of resting energy expenditure (REE) was performed based on oxygen consumption (VO2, ml/min) and carbon dioxide production (VCO2, ml/min). The value calculated by the metabolic cart was regarded as the measured REE (MREE). The simplified Weir formula was used in the calculation:[13] REE (kcal/d) = (3.94 × VO2 + 1.106 × VCO2) × 1.44. The predicted rest energy consumption (PREE) was automatically calculated by the metabolic cart using the Harris-Benedict (H-B) formula.[14] PREE (male, kcal/d) = 66.47 ± 13.77 × height (cm) × 6.25 × age (year) – 1.25 × body weight (kg) + 5.03 ± 1.00 × 4.9563 × age (year); or PREE (female, kcal/d) = 655.0955 ± 9.5634 × body weight (kg) + 1.8496 × height (cm) – 4.6750 × age (year). REE% = MREE/PREE < 90% was considered as low metabolism, 90% to 110% was considered as normal metabolism, and >110% was considered as high metabolism.[20]

The respiratory quotient (RQ) was the ratio of VCO2 to VO2 per unit of time: RQ = VCO2/VO2, representing the ratio of the 3 major nutrients. RQ was different if oxidizing substrates were different. RQ of 100% carbohydrate was 1.0, RQ of 100% fat was 0.7, RQ of 100% protein was 0.8, and RQ of mixed nutrients was 0.85 to 0.90.

Urine at 24 hours was collected, and quantitative measurement of urea nitrogen was tested using an AU5400 automatic biochemical analyzer (Olympus, Tokyo, Japan). The oxidation rate of the 3 major nutrients was automatically calculated using the following equation: 

\[ \text{Oxidation rate} = \text{Oxidation rate of CHO} + \text{Oxidation rate of FAT} + \text{Oxidation rate of PRO} \]

The respiration quotient (RQ) was the ratio of VCO2 to VO2 per unit of time: 

\[ \text{RQ} = \frac{\text{VCO2}}{\text{VO2}} \]

The ratio of VCO2 to VO2 was used to represent the ratio of the 3 major nutrients. The ratios were different if oxidizing substrates were different. The RQ of 100% carbohydrate was 1.0, RQ of 100% fat was 0.7, RQ of 100% protein was 0.8, and the RQ of mixed nutrients was 0.85 to 0.90.

2.5. Statistical analysis

Normal distribution was tested using the Kolmogorov-Smirnov test for continuous data. Continuous data meeting the normal distribution were presented as means ± standard deviation (SD) and analyzed using the independent sample t test. Data not meeting the normal distribution were presented as median (range) and analyzed using the Mann-Whitney U test. Categorical data were expressed as frequency (percentage) and analyzed using the chi-square test or Fisher exact test. Correlation analyses were performed using the Pearson correlation coefficient. Statistical analysis was performed using SPSS 23.0 (IBM, Armonk, NY). Two-sided P values < .05 were considered statistically significant.

3. Results

3.1. Baseline characteristics

Table 1 shows the baseline characteristics of the 2 groups of patients. There were 80 patients in the HCC group and 75 in the LC group. There were no significant differences in age, gender, and BMI (body mass index) between the 2 groups (age, 52.0 ± 8.41 vs 49.40 ± 10.17, P = .081; gender, male, 73 (91.3%) vs 63 (84%), P = .169; BMI, 22.63 ± 3.83 vs 23.63 ± 3.55, P = .096).

According to the Child-Pugh classification, the HCC and LC groups were divided into 3 subgroups, respectively, including 33 patients in the HCC-A group, 33 in the HCC-B group, 14 in the HCC-C group, 23 in the LC-A group, 30 in the LC-B group, and 22 in the LC-C group. There was no significant difference in the distribution of the Child-Pugh grades between the 2 groups (grade A 41.3% vs 30.7%; grade B 41.3% vs 40%; grade C 17.5% vs 29.3%, P = .170). According to the Barcelona Clinic Liver Cancer Staging, HCC patients were divided into 4 groups, including 33 patients (41.3%) in stage A (HCC-1 group), 13 (16.2%) in stage B (HCC-2 group), 21 (26.3%) in stage C (HCC-3 group), and 13 (16.3%) in stage D (HCC-4 group).

3.2. Indicators of liver functions

Table 2 presents the indicators of liver functions of the 2 groups. Comparison between the HCC and LC groups showed that TB (mmol/L) was lower (24.4 (18.3–37.9) mmol/L vs 30.1 (18.9–60.1) mmol/L, P = .039), TBA (mmol/L) was lower (20.8 (11.5–57.1) mmol/L vs 35.2 (19.0–83.5) mmol/L, P = .016), ALB (g/L) was higher significantly (35.5 ± 6.6 g/L vs 31.9 ± 6.6 g/L, P < .001), GGT (U/L) was higher (134.2 (53.9–257.1) U/L vs 53.7 (31.9–98.7) U/L, P < .001), AKP (U/L) was higher (126.5 (79.3–220.7) U/L vs 95.0 (69.3–133.8) U/L, P = .004), TC (mmol/L) was lower (3.805 (3.245–4.5) mmol/L vs 3.51 (2.65–4.08) mmol/L, P = .016), LDL-C (mg/dL) was higher (2.14 (1.73–2.8) mg/dL vs 1.89 (1.34–2.36) mg/dL, P = .006), and CHE (U/L) was higher (326.5 (225.7–5218.5) U/L vs 2882 (2083–4583) U/L, P = .368). Comparison between the HCC and LC groups showed that ALT and AST were slightly higher, but without significant difference.

### Table 1

| Characteristics of the patients. | LC n=75 | HCC n=80 | P |
|----------------------------------|---------|----------|---|
| Gender (male)                    | 63 (84.0%) | 73 (91.3%) | .169 |
| Age (yr)                         | 49.4 ± 10.2 | 52.0 ± 8.4 | .081 |
| BMI                              | 23.63 ± 3.55 | 22.63 ± 3.83 | .096 |
| Child-Pugh                       | .170 |
| A                                | 23 (30.7) | 33 (41.3%) | |
| B                                | 30 (40.0) | 33 (41.3%) | |
| C                                | 22 (29.3) | 14 (17.5%) | |
| BCLC                             | Stage A 33 (41.3%) | Stage B 13 (16.2%) | |
|                                  | Stage C 21 (26.3%) | Stage D 13 (16.3%) | |
| Tumor diameter (cm)              | 5.1 (2.6–11.6) | |

Child classes: A, 5–6 points; B, 7–9 points; C, 10–15 points. BCLC = Barcelona Clinic Liver Cancer, BMI = body mass index.
Table 2
Comparison of liver function between the 2 groups.

| Item                | LC (n = 75) | HCC (n = 80) | P     |
|---------------------|------------|--------------|-------|
| ALT (U/L)           | 36.2 (27.1–63.7) | 36.4 (28.0–62.0) | .596  |
| AST (U/L)           | 45.3 (33.7–78.1) | 58.9 (33.1–123.2) | .220  |
| TB (μmol/L)         | 30.1 (18.9–60.1) | 24.4 (18.3–37.9) | .039  |
| DB (μmol/L)         | 13.6 (6.6–25.7) | 9.10 (5.4–15.60) | .085  |
| ALB (g/L)           | 3.19 ± 0.66 | 3.55 ± 0.56 | <.001 |
| GLOB (g/L)          | 29.9 ± 7.2 | 29.2 ± 5.1 | .517  |
| GGT (U/L)           | 53.7 (31.9–98.7) | 134.2 (53.9–257.1) | <.001 |
| AKP (U/L)           | 95.0 (69.3–133.8) | 126.5 (79.5–220.7) | .004  |
| CHE (2882 – 2065–453) | 2620.5 (2257.5–5218.5) | .368  |
| TBA (μmol/L)        | 25.2 (10.0–83.5) | 20.2 (11.5–76.1) | .016  |
| CREA (μmol/L)       | 64.0 ± 15.5 | 60.6 ± 14.5 | .161  |
| Urea (mmol/L)       | 5.16 ± 1.62 | 4.93 ± 1.59 | .384  |
| GLU (mmol/L)        | 5.79 ± 2.60 | 5.31 ± 1.82 | .180  |
| INR (%)             | 67.2 ± 21.5 | 80.3 ± 16.1 | <.001 |
| AFP (ng/mL)         | 1.33 ± 0.26 | 1.17 ± 0.17 | <.001 |
| AST (U/L)           | 6.22 (3.03–59.70) | 50.63 (5.93–207.7) | .001 |
| TGO (μmol/L)        | 0.79 (0.54–1.19) | 0.87 (0.67–1.13) | .190  |
| TC (mmol/L)         | 3.51 (2.65–4.08) | 3.805 (2.345–4.15) | .146  |
| HDL-C (mmol/L)      | 0.92 (0.68–1.17) | 1.015 (0.8–1.45) | .146  |
| LDL-C (mmol/L)      | 1.89 (1.34–2.36) | 2.14 (1.73–2.8) | .006  |
| Apo A1 (g/L)        | 0.90 (0.60–1.16) | 0.96 (0.74–1.18) | .494  |
| Apo B (g/L)         | 0.64 (0.49–0.87) | 0.74 (0.66–0.89) | .020  |

**APP** = α-fetoprotein, **AKP** = alkaline phosphatase, **ALB** = albumin, **ALT** = alanine transaminase, **AST** = aspartate transaminase, **CHE** = cholesterol, **CREA** = creatinine, **DB** = direct bilirubin, **GGT** = γ-glutamyl transpeptidase, **GLU** = glucose, **GLOB** = globulin, **HDL-C** = high-density lipoprotein cholesterol, **INR** = international normalized ratio, **LDL-C** = low-density lipoprotein cholesterol, **PTA** = prothrombin time activity, **TBA** = total bilirubin, **TCA** = total cholesterol, **TG** = total triglycerides.

Statistical significance. There were no significant differences in renal functions between the two groups. **P** (%) was higher in the HCC group compared to the LC group (80.3 ± 16.1 vs 67.2 ± 21.5, **P < .001**), while INR was lower (1.17 ± 0.17 vs 1.33 ± 0.26, **P < .001**), suggesting that indicators of liver synthesis and metabolism of patients with HCC were better than those with LC. **AFP** (ng/mL) in the HCC group was significantly higher compared to the LC group (50.63 (5.93–207.7) ng/mL vs 6.22 (3.03–59.70) ng/mL, **P = .001**). In this study, the level of **AFP** in HCC group was lower than the diagnostic criteria (**AFP > 500 ng/mL**), suggesting that the possibility of hepatocellular carcinoma with normal or low levels of **AFP**.

Table 3 shows the indicators of liver function between the two groups with the same BCLC classification. Compared to the LC-A group, **INR** (1.07 ± 0.09 vs 1.14 ± 0.13, **P = .019**) and **TBA (μmol/L)** (13.1 (5.3–20.8) mmol/L vs 19.7 (11.9–28.8) mmol/L, **P = .018**) were lower in the HCC-A group, while there were no significant differences in the other indicators. Compared to the LC-B group, **AST (U/L)** (71.1 (44.3–128.6) U/L vs 42.85 (34.4–57.8) U/L, **P = .002**) was higher, **ALB (g/L)** was higher (33.0 ± 6.52 g/L vs 30.66 ± 7.48 g/L, **P = .028**), **GGT (U/L)** was higher (164.5 (70.2–258.05) U/L vs 46.05 (32.5–83.1) U/L, **P < .001**), and **AKP (U/L)** was higher (140.35 (99.9–231.35) U/L vs 84.15 (70.1–114.2) U/L, **P < .001**) in the HCC-B group, while the other indicators were not significantly different. Compared with the LC-C group, the HCC-C group was higher (142.55 (67.7–236.2) U/L vs 75.9 (50.9–113.5) U/L, **P = .036**) (g/L), **LDL-C (mmol/L)** was higher (3.33 ± 0.52 g/L vs 3.66 ± 0.74 g/L, **P = .028**) (mmol/L) vs 4.58 (3.14–4.86) mmol/L vs 2.58 (2.33–3.57) mmol/L, **P = .048**) (mmol/L) vs 2.16 (0.92–1.9) mmol/L, **P = .003**) (mmol/L) vs 1.31 (0.68–1.31) mmol/L, while the other indicators were not significantly different. The results suggest that with the aggravation of liver damage, improvement of liver synthesis and metabolic indicators were more significant in the HCC group compared to the LC group.

Table 4 shows the liver function indicators for HCC patients with different BCLC stages. The results suggested that with worsening tumor stage, liver damage of patient aggravated, ALT
Table 4
Comparison of the difference of liver function in patients with hepatocellular carcinoma according to Barcelona staging.

| Stage A | Stage B | Stage C | Stage D |
|---------|---------|---------|---------|
| HCC-1 (n = 33) | HCC-2 (n = 13) | HCC-3 (n = 21) | HCC-4 (n = 13) |
| ALT (U/L)  | 35.1 (28.6–59.5) | 29.7 (23.2–36.1) | 38.1 (30.5–67.9) | 48.3 (36.5–71.8) |
| AST (U/L) | 40.6 (31.1–82.9) | 44.2 (32.7–68) | 64.6 (56.1–128.6) | 161.9 (89.5–236.2) |
| TB (μmol/L) | 21.7 (15.7–36.2) | 21.7 (18.8–34.8) | 24.7 (19.9–30.7) | 38.9 (27.1–145.2) |
| DB (μmol/L) | 7 (5.1–13.5) | 7.2 (5.7–14) | 8.4 (4.4–13.3) | 24.4 (14.2–75) |
| ALB (g/L) | 35.9 ± 5.08 | 34.28 ± 4.08 | 37.6 ± 6.38 | 32.03 ± 5.37 |
| GLO (g/L) | 29.24 ± 5.5 | 28.45 ± 5.59 | 28.56 ± 4.79 | 31.07 ± 4.2 |
| GGT (U/L) | 69.85 (59–183) | 81.5 (53.9–156.5) | 178.5 (63.6–259) | 401.8 (163.8–506) |
| ALP (U/L) | 115.35 (75.75–140.35) | 79.3 (65.4–185.1) | 138.1 (91.3–252.9) | 230.1 (162.1–355.1) |
| CHE (U/L) | 3648 (2465–2224) | 2973 (2157–4272) | 4788 (2227–6811) | 1951 (1496–2656) |
| TBIL (μmol/L) | 16.4 (7.7–39.1) | 19.7 (15.4–57.4) | 13.9 (7.2–31.8) | 103.3 (67.1–167.1) |
| GLU (mmol/L) | 5.21 ± 1.36 | 5.61 ± 1.19 | 5.53 ± 2.87 | 4.9 ± 1.11 |
| PTA (%) | 79.82 ± 19.6 | 70.31 ± 14.3 | 84.9 ± 11.38 | 75.08 ± 14.22 |
| INR | 1.19 ± 0.19 | 1.16 ± 0.16 | 1.1 ± 0.12 | 1.24 ± 0.16 |
| APP (ng/mL) | 27.87 (5.62–483.6) | 16.75 (7.04–9240) | 67.06 (2.69–8836) | 926.2 (134.4–9418) |
| TG (mmol/L) | 0.825 (0.67–1.1) | 0.81 (0.59–1.13) | 0.915 (0.625–1.14) | 0.97 (0.68–1.23) |
| TC (mmol/L) | 3.77 (3.22–4.31) | 4.02 (3.45–4.19) | 4.41 (3.42–4.78) | 3.68 (3.01–4.86) |
| HDLC (mmol/L) | 1.09 (0.83–1.34) | 1.01 (0.74–1.26) | 1.00 (0.02–1.25) | 0.63 (0.37–0.97) |
| LDL (mmol/L) | 2.045 (1.375–2.775) | 2.14 (1.905–2.465) | 2.435 (2.02–3.35) | 2.41 (1.89–3.36) |
| Apo A1 (g/L) | 1.085 (0.875–1.26) | 0.865 (0.685–1.155) | 1.02 (0.855–1.165) | 0.64 (0.42–0.73) |
| Apo B (g/L) | 0.71 (0.635–0.895) | 0.72 (0.58–0.76) | 0.75 (0.68–1.01) | 0.78 (0.66–0.95) |

Table 5
Comparison of energy metabolism indexes between the 2 groups.

| LC (n = 75) | HCC (n = 80) | P |
|------------|-------------|---|
| MREE (kcal/d) | 1468.4 ± 355.31 | 1396.93 ± 332.62 kcal/d | .199 |
| FREE (kcal/d) | 1530.41 ± 220.97 | 1471.2 ± 234.32 kcal/d | .108 |
| REE% | 96.12 ± 18.99 | 95.58 ± 19.65% | .863 |
| RO | 0.85 ± 0.08 | 0.83 ± 0.07 | .703 |
| CHO (%) | 49 (31–62) | 35.5 (27–51) | .013 |
| CHO (kcal/d) | 609 (389.3–811.72) | 471.245 (390.68–695.83) | .028 |
| FAT (%) | 33 (18–52) | 41 (29–58) | .030 |
| FAT (kcal/d) | 449 (272.8–695.75) | 568.875 (372.47–820.215) | .100 |
| PRO (%) | 18 (14–24) | 18.5 (13–24) | .946 |
| PRO (kcal/d) | 246.7 ± 4 (180.28–297.7) | 254.13 (169.585–328.82) | .957 |

P = .120 and AST (P = .001) elevated, TB (P = .035) and DBil (P = .008) increased, ALB (P = .065) and CHE (P = .001) decreased, PTA (P = .310) reduced, while TC and LDL-C increased. Meanwhile, the indicators of liver synthetic functions improved in the HCC-3 group, which meant that ALB, CHE, and PTA increased, while INR decreased. Nevertheless, the above indicators were worse in the HCC-4 group. GGT and AKP increased significantly in the HCC-3 and HCC-4 groups compared to the HCC-1 and HCC-2 groups (P < .05).

3.3. Indicators of energy metabolism

Table 5 shows the indicators for energy metabolism between the 2 groups. Compared to the LC group, in the HCC group, both REE (kcal/d) and REE% were lower, but without significant difference (1396.93 ± 332.62 kcal/d vs 1468.4 ± 355.31 kcal/d, P = .199; 95.58 ± 19.65% vs 96.12 ± 18.99%, P = .863), RQ was lower (0.83 ± 0.07 vs 0.85 ± 0.08, P = .073), CHO% was lower (35.5 (27–51)% vs 49 (31–62)%), FAT% was higher (41 (29–58)% vs 33 (18–52)%), and RPO% was slightly higher (18.5 (13–24)% vs 18 (14–24)%, P = .946). The results suggest that patients in the HCC and LC groups had normal energy metabolism, but the proportions of the 3 major nutrients in the HCC group were unbalanced, and fat oxidation was the main energy supply.

Table 6 shows the differences in indicators of energy metabolism for patients in the HCC group with different Child-Pugh grades. The results showed that with the deterioration of liver functions, although MREE showed a progressive increasing trend (1380.82 ± 333.21 vs 1401.15 ± 336.91 vs...
Comparison of energy metabolism among different Child-Pugh grades in patients with carcinoma.

|        | HCC-A (n = 33) | HCC-B (n = 33) | HCC-C (n = 14) | P     |
|--------|---------------|---------------|---------------|-------|
| MREE (kcal/d) | 1380.82 ± 333.21 | 1401.15 ± 336.91 | 1424.93 ± 343.62 | 0.991 |
| FREE (kcal/d)  | 1486.73 ± 307.8 | 1471.49 ± 273.85 | 1433.93 ± 201.66 | 0.566 |
| REE%       | 93.28 ± 19.98  | 90.57 ± 21.28  | 96.67 ± 14.37  | 0.582 |
| RQ         | 0.85 ± 0.06    | 0.82 ± 0.07    | 0.8 ± 0.08     | 0.085 |
| CHO (%)    | 39 (33–58)      | 34 (26.5–48)  | 28 (21–49)     | 0.097 |
| CHO (kcal/d) | 510.68 (435.93–856.66) | 455.7 (320.42–637) | 354.0 (290.6–573.6) | 0.102 |
| FAT (%)    | 40 (24–52)      | 41 (29–59)     | 55.5 (34–70)   | 0.150 |
| FAT (kcal/d) | 499.32 (282.26–55.5) | 579.15 (452.4–1017.1) | 738.44 (452.4–1017.1) | 0.173 |
| PRO (%)    | 19 (13–26)      | 16 (13–24)     | 19.5 (14–26)   | 0.984 |
| PRO (kcal/d) | 253.5 (171.73–339.71) | 239.52 (172.05–308.64) | 290.2 (167.44–331.44) | 0.850 |

CHO% = carbohydrate oxidation rate, CHO = carbohydrate oxidation, FAT% = fat oxidation rate, FAT = fat oxidation, MREE = resting energy consumption, FREE = predict rest energy expenditure, PRO% = protein oxidation rate, PRO = protein oxidation, RQ = respiratory quotient.

Comparison of energy metabolism in different stages of liver cancer according to Barcelona staging.

Table 7 shows the correlation between liver functions and energy metabolism in HCC patients. AST was negatively correlated with CHO% (r = -0.18409, P = 0.0418). GGT was negatively correlated with CHO% (r = -0.20043, P = 0.0127). AKP was negatively correlated with RQ% (r = -0.26110, P = 0.0011), CHO% (r = -0.26461, P = 0.0011), and CHO (r = -0.23134, P = 0.0039), while positively correlated with FAT% (r = 0.21629, P = 0.0071) and FAT (r = 0.19526, P = 0.0152). CHE was positively correlated with RQ (r = 0.21393, P = 0.0075), CHO% (r = 0.16206, P = 0.0468), while negatively correlated with FAT% (r = -0.20454, P = 0.0107) and FAT (r = -0.18409, P = 0.0219). TBA was negatively correlated with RQ (r = -0.17568, P = 0.0293) and CHO (r = -0.16841, P = 0.0368), while positively correlated with FAT (r = 0.15987, P = 0.0476). TC was positively correlated with PRO% (r = 0.41659, P < 0.0001) and PRO (r = 0.30928, P < 0.0001).

Comparison of energy metabolism in different stages of liver cancer according to Barcelona staging.

|        | Stage A | Stage B | Stage C | Stage D | P     |
|--------|---------|---------|---------|---------|-------|
| MREE (kcal/d) | 1482.64 ± 311.17 | 1344.92 ± 230.61 | 1267.86 ± 281.01 | 1449.85 ± 344.24 | 0.060 |
| FREE (kcal/d)  | 1552.33 ± 261.16 | 1436.15 ± 178.34 | 1389.76 ± 206.51 | 1431.85 ± 209.73 | 1.000 |
| REE%       | 96.6 ± 18.92   | 93.62 ± 15.32   | 92.16 ± 25.77   | 100.46 ± 13.93   | 0.708 |
| RQ         | 0.84 ± 0.05    | 0.79 ± 0.08*    | 0.84 ± 0.06     | 0.81 ± 0.08     | 0.082 |
| CHO (%)    | 36 (32–51)     | 28.5 (20–41)    | 36 (28–54)      | 29 (24–50)      | 0.170 |
| CHO (kcal/d) | 545.24 (462.4–738.09) | 434.93 (320.42–777.6) | 358.8 (305.37–573.6) | 0.026 |
| FAT (%)    | 38 (29–53)     | 53 (43–67)      | 40 (28–53)      | 55 (34–80)      | 0.094 |
| FAT (kcal/d) | 525.54 (380.4–801.15) | 684.64 (552.98–1015.3) | 460.65 (217.93–713.34) | 669.76 (452.4–1017.1) | 0.183 |
| PRO (%)    | 17 (12–27)     | 19 (15–22)      | 19 (15–20)      | 20 (15–20)      | 0.802 |
| PRO (kcal/d) | 254.76 (166.18–344.6) | 192.64 (161.85–282.26) | 238.51 (172.05–300.7) | 305.4 (195.14–331.44) | 0.460 |

CHO% = carbohydrate oxidation rate, CHO = carbohydrate oxidation, FAT% = fat oxidation rate, FAT = fat oxidation, MREE = resting energy consumption, FREE = predict rest energy expenditure, PRO% = protein oxidation rate, PRO = protein oxidation, RQ = respiratory quotient.

* represents compared to HCC-1 group, P < .05.
† represents compared to HCC-3, P < .05.
Table 8
Correlations between energy metabolism and liver function in patients with carcinoma.

|        | RQ     | CHO (%) | FAT (%) | PRO (%) |
|--------|--------|---------|---------|---------|
| ALT    | -0.06356 | -0.08202 | -0.09778 | 0.03845 | -0.00919 | -0.01359 |
|        | 0.4320  | 0.3167  | 0.2261  | 0.3629  | 0.6348  | 0.9102  | 0.8668  |
| AST    | -0.14293 | -0.17067 | -0.16372 | 0.11096 | 0.12109 | 0.11249 | 0.13054 |
|        | 0.0760  | 0.0362  | 0.0418  | 0.1693  | 0.1334  | 0.1662  | 0.1054  |
| ALB    | 0.14363 | 0.11030 | 0.08330 | -0.13313 | -0.13829 | 0.00216 | -0.05576 |
|        | 0.0746  | 0.1776  | 0.3028  | 0.0967  | 0.0862  | 0.9789  | 0.4908  |
| GLOB   | 0.07104 | 0.05229 | 0.12367 | -0.08687 | -0.03154 | 0.10165 | 0.17807 |
|        | 0.3797  | 0.5237  | 0.1252  | 0.2825  | 0.6968  | 0.2112  | 0.0266  |
| TBA    | -0.15020 | -0.15154 | -0.20043 | 0.12442 | 0.11720 | 0.08072 | 0.08314 |
|        | 0.0630  | 0.0641  | 0.0127  | 0.1242  | 0.1478  | 0.3229  | 0.3035  |
| AKP    | -0.26310 | -0.26461 | -0.23134 | 0.21629 | 0.19526 | 0.11235 | 0.14515 |
|        | 0.0011  | 0.0011  | 0.0039  | 0.0071  | 0.0152  | 0.1682  | 0.0725  |
| CHE    | 0.21393 | 0.16206 | 0.14596 | -0.20454 | -0.18409 | 0.02090 | 0.00690 |
|        | 0.0075  | 0.0468  | 0.0700  | 0.0107  | 0.0219  | 0.7976  | 0.9321  |
| GGT    | -0.17568 | -0.09234 | -0.16841 | 0.14617 | 0.15987 | -0.01644 | 0.01324 |
|        | 0.0293  | 0.2611  | 0.0368  | 0.0705  | 0.0476  | 0.8407  | 0.6706  |
| PTA    | 0.10386 | 0.04883 | -0.01120 | -0.10463 | -0.12246 | 0.07072 | 0.00323 |
|        | 0.1084  | 0.5516  | 0.8800  | 0.1951  | 0.1290  | 0.3889  | 0.9969  |
| INR    | -0.07199 | 0.02226 | 0.03174 | 0.07201 | 0.10442 | -0.10367 | -0.05262 |
|        | 0.3734  | 0.7862  | 0.6651  | 0.3733  | 0.1960  | 0.2022  | 0.5155  |
| AFR    | -0.01863 | -0.03226 | -0.00717 | 0.04846 | 0.02832 | -0.08781 | -0.05880 |
|        | 0.8180  | 0.6941  | 0.2925  | 0.5433  | 0.7265  | 0.2804  | 0.4674  |
| TG     | -0.00914 | -0.00047 | -0.10444 | 0.06044 | 0.12924 | 0.04029 | 0.01410 |
|        | 0.6333  | 0.2758  | 0.2019  | 0.4610  | 0.1137  | 0.6256  | 0.8636  |
| TC     | 0.06979 | -0.00918 | -0.006647 | -0.11413 | -0.09971 | 0.41659 | 0.30928 |
|        | 0.3882  | 0.9019  | 0.4112  | 0.1573  | 0.2171  | <0.001  | <0.001  |
| HDL-C  | -0.00207 | 0.02623 | -0.03511 | -0.01530 | -0.01398 | -0.00065 | -0.00156 |
|        | 0.9800  | 0.7550  | 0.6718  | 0.8535  | 0.8661  | 0.9997  | 0.9850  |
| LDL-C  | 0.07227 | 0.01630 | -0.009915 | -0.07801 | -0.09223 | 0.12751 | 0.04402 |
|        | 0.3778  | 0.8447  | 0.2258  | 0.3410  | 0.2600  | 0.1212  | 0.5915  |
| Apo A1 | 0.14133 | 0.07534 | 0.06790 | -0.16871 | -0.15623 | 0.12911 | 0.18817 |
|        | 0.0845  | 0.3661  | 0.4084  | 0.0390  | 0.0562  | 0.1178  | 0.0211  |
| Apo A2 | 0.04175 | -0.02707 | -0.06050 | -0.05147 | 0.01136 | 0.13856 | 0.13050 |
|        | 0.6132  | 0.7465  | 0.4636  | 0.5330  | 0.8906  | 0.0942  | 0.1127  |

**AFR** = alpha-fetoprotein, **APK** = alkaline phosphatase, **ALB** = albumin, **ALT** = alanine transaminase, **Apo A1** = Apolipoprotein A-1, **Apo B** = Apolipoprotein B, **AST** = aspartate transaminase, **CHE** = cholesterol ester, **CHO** = carbohydrate oxidation rate, **CHO** = carbohydrate oxidation, **CREA** = creatinine, **DB** = direct bilirubin, **Fat%** = fat oxidation rate, **Fat%** = fat oxidation, **GCT** = γ-glutamyltranspeptidase, **GLOB** = globulin, **GLU** = glucose, **HDL-C** = high-density lipoprotein cholesterol, **INR** = international normalized ratio, **LDL-C** = low-density lipoprotein cholesterol, **PRO%** = protein oxidation rate, **PRO** = protein oxidation, **PTA** = prothrombin time activity, **RQ** = respiratory quotient, **TB** = total bilirubin, **TBA** = total bile acids, **TC** = total cholesterol, **TG** = total triglycerides.

4. Discussion
In this study, the Child-Pugh scores were not statistically different between the HCC and LC groups, but ALB, CHE, TC, PTA, and INR in the HCC group were higher compared to the LC group, suggesting that the liver synthetic function was better in the HCC group. With the aggravation of liver damage, liver functions of the HCC group were still better than in the corresponding LC groups. An early study by Guglielmi et al. also revealed that ALB levels in the HCC group were high. It is well known that ALB levels are associated with prognosis, which explains why it can be observed that the prognosis of some patients with HCC is better than for patients with cirrhosis.
About 75% of TC is synthesized by the liver. LDL-C is the lipoprotein with the highest cholesterol content. LDL-C is mainly synthesized by liver cells and its structural protein is apolipoprotein B. The levels of cholesterol and lipoprotein reflect the function of hepatocyte synthesis. Previous studies have shown that secretion of liver cholesterol and lipoprotein decrease with the progression of cirrhosis. In this study, TC, LDL-C, and ApoB in the HCC group were higher than in the LC group, suggesting that the synthetic function of liver was better in the HCC group.

In the present study, GGT and AKP in the HCC group were higher than in the LC group, suggesting that GGT and AKP can be used as predictors of hepatocellular carcinoma. Serum GGT is mainly derived from the hepatobiliary system. Therefore, serum GGT increases when bile acid synthesis increases or bile excretion is blocked. In this study, GGT was higher in the HCC group, while TB and TBA were lower, which were considered to be caused by secretion of HCC instead of non-tumor invasion of the biliary tract or disorder of biliary excretion. Previous studies have shown that HCC cells can secrete GGT. Since the reverse differentiation of cancer cells is like the embryonic stage (the GGT content in the embryonic liver cells is about 30 times that of adulthood), the production of GGT increases. Meanwhile, the cancer tissue itself or surrounding inflammatory stimuli enhance the permeability of the liver cell membrane. Therefore, blood GGT is further elevated. Studies have shown that GGT levels are associated with the prognosis of HCC and cirrhosis.

AKP is a marker of liver or bone diseases and is also associated with cancer. Increased AKP is associated with worsening prognosis of HCC. In this study, AKP in the HCC group was significantly higher than in the LC group, and with the progression of tumor stages, both AKP and GGT gradually increased, thus reflecting the occurrence and progression of HCC.

As we have found in our study, some indicators of liver synthetic function were better in the HCC group compared to the LC group, especially in patients with Child-Pugh grade C, suggesting that HCC cells may have the effect of compensating liver function deficits in patients with cirrhosis. For large hepatocellular carcinoma, if the tumor is removed, the compensation mechanism disappears and liver function deteriorates. Because of the compensation mechanism of HCC, the true liver functions before surgery are covered for this part of patients with cirrhosis, resulting in an illusion of good functions. Therefore, in clinical practice, we can observe that some patients with large HCC develop liver failure after surgery, and the condition deteriorates sharply. It has been confirmed that cancer cells can have certain properties of the source cells. For example, keratin can still be synthesized in epithelial cancers and the HCC cells can express hepatocyte markers in the embryonic stage such as AFP, EP-CAM, and CK8. Cancer cells, especially those mature cells in the final stage of differentiation, can express metabolites of normal liver cells such as ALB and GGT. The metabolites they produce also play their corresponding role in the body, thereby compensating for the dysfunction of hepatocytes during cirrhosis. It has been reported that there are frequent cell communication between HCC cells and normal liver cells, and there is bi-directionality in their communication. HCC cells have a mechanism that allows them to function as part of normal liver cells, compensating for the dysfunction caused by excessive cirrhosis and necrotic cells.

Energy metabolism refers to the energy production and utilization process of nutrients (mainly glucose, fat, and protein) in the body. Because measurement of REE is convenient and practical and can reflect the total energy consumption of the body every day, it is a common indicator for clinical study of human metabolic consumption. At present, there are few studies on energy metabolism of liver cirrhosis and related HCC using a metabolic cart. Previous studies have shown that patients with cirrhosis have low metabolism, characterized by low CHO% and with proteins as the main energy supply. It is still controversial whether the reduction or increase of REE is correlated with cirrhosis, but non-protein RQ is associated with the prognosis of liver cirrhosis and HCC. Previous studies by Wu et al showed that patients with malignant tumors were not in a state of high metabolism, 24% of patients with malignant tumors were in low metabolic state, 46% of patients with malignant tumors were in normal metabolic state, and 30% of patients with malignant tumors were in high metabolic state. In this study, metabolic carts were used to analyze the energy metabolism of patients in the LC and HCC groups. The results showed that both HCC and LC patients had a normal metabolic state. REE and REE% in HCC patients were slightly lower compared to LC patients, but there was no significant difference for REE and REE%. REE% was significantly higher in patients with large HCC and there was high metabolism, suggesting that energy metabolism was related to liver functions and tumor size. Previous studies have shown that CHO% decreases with the aggravation of cirrhosis, while PRO% increases. In this study, CHO% of both groups showed a decreasing trend, which decreased more significantly in the HCC group. Nevertheless, FAT% increased, suggesting that energy supply of the 3 major nutrients changed in the HCC group, which was mainly fat oxidation. Moreover, with the deterioration of liver functions, RQ and CHO% progressively decreased in the HCC group, while FAT% progressively increased, suggesting that with the destruction of tumor cells to liver tissue, the energy supply pattern by glucose oxidation of liver cells gradually changed to energy supply pattern by fat oxidation of tumor cells. The results of the BCLC staging showed that with the progression of tumor stages, RQ and CHO% decreased in patients with HCC, while FAT% increased, suggesting that tumor progression aggravated malnutrition. There was significant change in the HCC-2 group compared to the HCC-1 group, suggesting that increase in the number and size of tumors led to liver damage and poor energy metabolism. Indicators of energy metabolism were especially deteriorated in the HCC-4 group, which was consistent with the significant deterioration of liver functions in the HCC-4 group. Nevertheless, changes in the indicators for energy metabolism in the HCC-3 group showed the opposite, which was considered to be because patients suffered from vascular invasion and metastasis of tumor during the period, thus the tumor was strong, the number of tumor cells was high, and functions also increased significantly. Therefore, performance of liver functions was improved. Improved liver functions resulted in the improvement of energy metabolism, but destruction of liver by tumor still aggravated. Thus, when tumor progressed to a certain degree, there would be deterioration of liver functions, as well as deterioration of energy metabolism, thus entering stage 4. Therefore, it suggested that the seemingly good indicators of liver functions do not represent truly good hepatocyte functions. The selection of clinical treatment options can not only refer to the indicators of liver functions, which should be evaluated comprehensively, and appropriate treatment plan should be adopted. Based on our findings, it could be recommended that...
active nutritional intervention should be performed starting from patients at BCLC2 stage to improve liver functions, thus improving nutritional status and prognosis of the patients.

Although RQ in the LC and HCC groups was basically normal, the proportions of the 3 major nutrients were inconsistent with that of normal people, manifesting as significant increase in fat oxidation and significant decrease in carbohydrate oxidation, which was consistent with previous studies. Changes of energy metabolism were similar to starvation condition, which may result in malnutrition. HCC was worse than cirrhosis, glucose oxidation was lower and fat oxidation was higher, thus aggravating fat decomposition and malnutrition. In patients with cancer, energy metabolism had its particularity due to the growth of tumors and metabolic changes in the body. A large number of studies in the 20th century demonstrated that resting energy metabolic rate of patients with malignant tumors was significantly higher than the predicted value and healthy control population. Nevertheless, some scholars in more recent years believe that resting energy expenditure of patients with malignant tumors does not increase significantly, but the body composition can be changed, manifesting as excessive fat consumption, emaciation, and even cachexia. The different cell proliferation cycles of tumor tissue can affect the metabolic process of various nutrients in the body, thus affecting the energy consumption of the body.

In this study, liver functions of patients with HCC improved compared to the LC group, but indicators of energy metabolism did not improve significantly. Moreover, with the progression of BCLC staging and aggravation of liver functions, energy metabolism deteriorated. Although HCC can improve the efficiency of glucose utilization through the glycolysis pathway, it cannot offset the reduction of RQ due to the consumption of lipids and proteins. In addition, HCC metabolic reprogramming may interfere with the pathways of glucose metabolism in other organs, which further reduces CHO%. Although hepatocellular carcinoma cells have the function of hepatocyte synthesis, they still consume nutrients and cannot improve the nutritional metabolism of patients. With the progression of tumors, the limited anabolic function cannot offset the damage caused by the tumor, resulting in severe malnutrition and even dyscrasia, aggravating liver damage, and finally leading to death. This study demonstrated that indicators of liver functions (AST, CHE, GGT, AKP, TBA, and TC) in patients with HCC were correlated with indicators of energy metabolism. CHE was positively correlated with RQ and CHO%, while GGT and AKP were negatively correlated with CHO. Therefore, monitoring of the above indicators may have guiding significance for tumor progression and nutritional therapy in patients.

5. Conclusions

In summary, this study found that patients in the HCC group had improved function of hepatocyte synthesis (ALB, TC, LDL-C, GGT, PTA, INR) than those in the LC group, suggesting that hepatocellular carcinoma cells may have function of hepatocyte synthesis, and partly compensate liver function deficits in cirrhosis. Therefore, patients with cirrhosis accompanying by hepatocellular carcinoma needed to correctly evaluate the true liver functions after removal of the tumor. Liver functions should not be evaluated simply based on Child-Pugh classification. Blind resection of large tumors may lead to liver function deterioration postoperatively. In the absence of proper treatment, “coexistence with cancer” may be a better choice. In this study, it was found that fat oxidation was the main energy supply for HCC patients. With tumor progression, liver functions deteriorated and energy metabolism worsened. However, indicators of liver functions were correlated with indicators of energy metabolism. In particular, CHE was positively correlated with CHO% and negatively correlated with FAT%. Therefore, patients with hepatocellular carcinoma should be actively supplied with nutrients in order to improve liver functions and nutritional status, thus the patients can obtain treatment opportunity and survival time of patients can be prolonged.

This study still had certain limitations. Firstly, this study was a retrospective single-center study, which was limited to the available data in medical charts. In addition, there was no follow-up, thus the long-term results cannot be obtained, such as survival time. In addition, the theory of “liver function compensation” of hepatocellular carcinoma cells still needed to be further investigated by large samples and basic research.

Author contributions

Conceptualization: Meixin Ren.

Data curation: Meixin Ren, Qing-Hua Meng.

Formal analysis: Juan Li, Shengli Li Coll.

Investigation: Qing-Hua Meng.

Methodology: Meixin Ren, Ran Xue, Qing-Hua Meng.

Project administration: Juan Li, Shengli Li Coll.

Software: Meixin Ren, Ran Xue, Zhongying Wang, Qing-Hua Meng.

Supervision: Juan Li, Shengli Li Coll.

Validation: Ran Xue, Shengli Li Coll.

Visualization: Meixin Ren, Juan Li, Zhongying Wang, Qing-Hua Meng.

Writing – original draft: Meixin Ren, Juan Li, Qing-Hua Meng.

Writing – review & editing: Meixin Ren, Juan Li.

References

[1] Meng QH, Hou W, Yu HW, et al. Resting energy expenditure and substrate metabolism in patients with acute-on-chronic hepatitis B liver failure. J Clin Gastroenterol 2011;45:456–61.

[2] Moriwaki H, Tajika M, Miwa Y, Okita K, et al. Energy metabolism in liver cirrhosis: its characteristics, clinical significance, and possible intervention. Liver Cirrhosis Tokyo: Springer; 2001.

[3] Yamanaka H, Genjida K, Yokota K, et al. Daily pattern of energy metabolism in cirrhosis. Nutrition 1999;15:749–54.

[4] Terakura Y, Shiraki M, Nishimura K, et al. Indirect calorimetry and anthropometry to estimate energy metabolism in patients with liver cirrhosis. J Nutr Sci Vitaminol (Tokyo) 2010;56:372–9.

[5] Turdean S, Gurzu S, Turcu M, et al. Current data in clinicopathological characteristics of primary hepatic tumors. Rom J Morphol Embryol 2012;53:719–24.

[6] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.

[7] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:113–38.

[8] Pinche P, Nagari H, Prigent S, et al. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene 1999;18:3127–34.

[9] Seyfried T. Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. Philadelphia: Wiley; 2012.

[10] Dagnelie PC, Sijens PE, Kraus DJ, et al. Abnormal liver metabolism in cancer patients detected by (31)P MR spectroscopy. NMR Biomed 1999;12:535–44.

[11] Lieffers JR, Mourtzakis M, Baade PD, et al. A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 2009;89:1173–9.
[12] Guglielmi FW, Mastronuzzi T, De Marco M, et al. Oxidative metabolism in cirrhotic patients with and without hepatocellular carcinoma: effects of malnutrition. Hepatology 1992;16:1144–9.

[13] Zhang L, Huang Y, Lian M, et al. Metabolic profiling of hepatitis B virus-related hepatocellular carcinoma with diverse differentiation grades. Oncol Lett 2017;13:1204–10.

[14] Fritan AI, Nelson DR, Liu C, et al. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS. Liver Int 2014;34:1428–44.

[15] Liu SY, Zhang RL, Kang H, et al. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013;19:3423–32.

[16] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–61.

[17] Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–74.

[18] Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Practice Guidelines Committee of the American Association for the Study of Liver Diseases: management of variceal hemorrhage in cirrhosis. Hepatology 2007;46:922–38.

[19] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.

[20] Hebuterne X, Hastier P, Peroux JL, et al. Resting energy expenditure and substrate metabolism in liver cirrhosis. J Hepatol 2012;56:0.

[21] Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med 2016;9:229–55.

[22] Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012;56:0–964.

[23] Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–74.

[24] Hann HW, Wan S, Myers RE, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012;7:e47687.

[25] Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013;1830:2481–95.

[26] Clark PA, Treisman DM, Ebben J, et al. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn 2007;236:3297–308.

[27] Ma H, Zhang L, Tang B, et al. gamma-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol 2014;21:1308–4–9.

[28] Lu Q, Song J, Huang Y, et al. The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: A Retrospective Cohort Study in China. Medicine (Baltimore) 2016;95:e3372.

[29] Lammers WJ, van Baaren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338–49. e1335;quiz e1315.

[30] Lopez JB, Balasegaram M, Thambirajah V, et al. The value of liver function tests in hepatocellular carcinoma. Malays J Pathol 1996;18:95–9.

[31] Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215–20.

[32] Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumor efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006;12:6523–31.

[33] Muller MJ, Brotcher J, Selberg O. Energy expenditure and substrate metabolism in liver cirrhosis. Int J Obes Relat Metab Disord 1993;17(Suppl 3):S102–106, discussion S115.

[34] Muller MJ, Fenk A, Lautz HU, et al. Energy expenditure and substrate metabolism in ethanol-induced liver cirrhosis. Am J Physiol 1991;260:E338–344.

[35] Merli M, Riggio O, Romiti A, et al. Basal energy production rate and catabolism of chronic pancreatitis. Dig Dis Sci 1996;41:533–9.

[36] Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med 2016;9:229–55.

[37] Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012;56:0–964.

[38] Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–74.

[39] Hann HW, Wan S, Myers RE, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012;7:e47687.

[40] Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013;1830:2481–95.

[41] Clark PA, Treisman DM, Ebben J, et al. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn 2007;236:3297–308.

[42] Ma H, Zhang L, Tang B, et al. gamma-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol 2014;21:1308–4–9.

[43] Lu Q, Song J, Huang Y, et al. The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B: A Retrospective Cohort Study in China. Medicine (Baltimore) 2016;95:e3372.

[44] Lammers WJ, van Baaren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338–49. e1335;quiz e1315.

[45] Lopez JB, Balasegaram M, Thambirajah V, et al. The value of liver function tests in hepatocellular carcinoma. Malays J Pathol 1996;18:95–9.

[46] Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215–20.

[47] Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumor efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res 2006;12:6523–31.

[48] Muller MJ, Brotcher J, Selberg O. Energy expenditure and substrate metabolism in liver cirrhosis. Int J Obes Relat Metab Disord 1993;17(Suppl 3):S102–106, discussion S115.

[49] Muller MJ, Fenk A, Lautz HU, et al. Energy expenditure and substrate metabolism in ethanol-induced liver cirrhosis. Am J Physiol 1991;260:E338–344.

[50] Merli M, Riggio O, Romiti A, et al. Basal energy production rate and catabolism of chronic pancreatitis. Dig Dis Sci 1996;41:533–9.

[51] Levitt DG, Levitt MD. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med 2016;9:229–55.

[52] Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012;56:0–964.

[53] Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439–74.

[54] Hann HW, Wan S, Myers RE, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012;7:e47687.

[55] Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013;1830:2481–95.

[56] Clark PA, Treisman DM, Ebben J, et al. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn 2007;236:3297–308.